Asher Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.asherbio.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
Phase 1
Recruiting
- Conditions
- Non Small Cell Lung CancerMelanomaRenal Cell CarcinomaSolid TumorSquamous Cell Carcinoma of Head and Neck
- Interventions
- Biological: etakafusp alfa (AB248)
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Asher Biotherapeutics, Inc.
- Target Recruit Count
- 552
- Registration Number
- NCT05653882
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸UCSD, San Diego, California, United States
News
No news found